Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILLUMINATE-B: Lumasiran in Infants and Young Children with Primary Hyperoxaluria Type 1
2018-004014-17Phase 3Unknown
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Dec 2018
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lumasiran in Primary Hyperoxaluria Type 1 (PH1) and hyperoxaluria, sponsored by Alnylam Pharmaceuticals. Status: unknown.
02
Drugs
lumasiran
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)hyperoxaluria
Beyond the preview
Go deeper on 2018-004014-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004014-17.